



3 April 2024

Privatisation by way of scheme of arrangement

Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Other types of securities (e.g. equity swaps)	Closing / flattening / unwinding of proprietary positions arising from unsolicited client-driven dealings. I confirm this was done no later than the close of the morning trading session on the trading day following the originating client-driven dealing	Purchase	183,000	\$12,182,728.8800	\$17.7847	\$17.7753
---	--	----------	---------	-------------------	-----------	-----------